Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

The discovery of biomarkers such as phospho-tau217 marked an important advancement in Alzheimer’s diagnosis. This particular ...

Manufacturers of Alzheimer’s disease drugs have identified blood tests as a way to accelerate diagnosis and treatment.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide ...

To measure amyloid-beta and tau in the brain, all participants underwent specialized brain imaging using positron emission ...

The pharma industry's dogged determination to develop amyloid-targeting therapies for Alzheimer's disease is a "road to nowhere", according to the scientist behind a rival approach. Claude Wischik ...

SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 ...

A study published in Brain Communications revealed new insights into early detection of Alzheimer’s disease. Researchers have ...